SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (19370)3/20/2006 9:21:44 PM
From: A.J. Mullen  Read Replies (1) of 52153
 
This could be a significant case for biotech if it is broadly decided. Wonder if MYGN (for example) might get hurt by an adverse ruling?

I'm hoping ( and betting) that the ruling won't be so broad as to affect MYGN. They've shown changes to specific genes cause or at least render people much more susceptible to particular cancers. That's stronger than mere correlation - although MYGN's contribution might not have been much more than establishing the correlation.

Genomic Health is another company whose business depends on correlations - with treatments this time. If they're able to keep their data confidential then a competitor would have to duplicate their biological analyses. I presume public institutions would not have granted exclusive access to samples from their patients. IS that a reasonable presumption?

Ashley
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News